PULMONARY HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE

B.T. Daminov; A.N. Abduvakhitova

doi:10.5281/zenodo.10682420

PULMONARY HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE

20.02.2024 International Scientific Journal "Science and Innovation". Series D. Volume 3 Issue 2

B.T. Daminov, A.N. Abduvakhitova

Abstract. Pulmonary hypertension (PH), concomitant with chronic kidney disease (CKD), is a serious but insufficiently focused disease and can lead to life-threatening conditions. Pathogenesis of LH is specific in CKD, and early diagnosis and timely appropriate treatment are important. Many studies have shown that the incidence of PH in CKD reaches almost 80% and in the future, is associated with an increase in mortality. WHO classified PH in CKD as group 5, that is, a polyetiological group of unclear genesis. Medical treatment of PH in patients with CKD is not very different from other etiologies. However, it should be understood that PH per se can be multifactorial, other secondary causes must also be recognized and addressed accordingly. In this article, we will try to discuss the concept of PH in the concept of CKD and treatment options

Keywords: chronic kidney disease, end-stage renal disease, pulmonary hypertension, cardiovascular diseases.

References:

1. J.D. Conger, W.S. Hammond, A.C. Alfrey, et al., Pulmonary Calcifications in chronic dialysis patients: clinical and Pathologic studies, Ann. Intern. Med. 83 (1975) 330–336. 2. Simonneau G, Robbins IM, Beghetti M, Chan- nick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43–S54. 3. Fabbian F, Cantelli S, Molino C, Pala M, Longhini C, Portaluppi F: Pulmonary hyper- tension in dialysis patients: a cross-sectional Italian study. Int J Nephrol 2010;2011:283475. 4. Unal A, Sipahioglu M, Oguz F, Kaya M, Kucuk H, Tokgoz B, Buyukoglan H, Oymak O, Utas C: Pulmonary hypertension in peritoneal dialysis patients: prevalence and risk factors. Perit Dial Int 2009;29:191–198. 5. Yigla M, Nakhoul F, Sabag A, Tov N, Gorev- ich B, Abassi Z, Reisner SA: Pulmonary hypertension in patients with end-stage renal disease. Chest 2003;123:1577–1582. 6. M. Partinen, C. Guilleminault, Daytime sleepiness and vascular morbidity at seven- year follow-up in obstructive sleep apnea patients, Chest 97 (1990) 27–32. 7. Yigla M, Fruchter O, Aharonson D, Yanay N, Reisner SA, Lewin M, Nakhoul F: Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients. Kidney Int 2009;75:969–975. 8. Havlucu Y, Kursat S, Ekmekci C, Celik P, Serter S, Bayturan O, Dinc G: Pulmonary hy- pertension in patients with chronic renal failure. Respiration 2007;74:503–510. 9. Abdelwhab S, Elshinnawy S: Pulmonary hypertension in chronic renal failure patients. Am J Nephrol 2008;28:990–997. 10. Agarwal R: Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Trans- plant 2012;27:3908–3914 11. Ramasubbu K, Deswal A, Herdejurgen C, Aguilar D, Frost AE: A prospective echocadiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Int J Gen Med 2010;3:279–286. 12. Unal A, Tasdemir K, Oymak S, Duran M, Kocyigit I, Oguz F, Tokgoz B, Sipahioglu MH, Utas C, Oymak O: The long-term effects of ar teriovenous fistula creation on the development of pulmonary hypertension in hemodialysis patients. Hemodial Int 2010;14:398–402. 13. Kumbar L, Fein PA, Rafiq MA, Borawski C, Chattopadhyay J, Avram MM: Pulmonary hypertension in peritoneal dialysis patients. Adv Perit Dial 2007;23:127–131 14. Yigla M, Keidar Z, Safadi I, Tov N, Reisner SA, Nakhoul F: Pulmonary calcification in hemodialysis patients: correlation with pulmonary artery pressure values. Kidney Int 2004;66: 806–810. 15. Nakhoul F, Yigla M, Gilman R, Reisner SA, Abassi Z: The pathogenesis of pulmonary hypertension in haemodialysis patients via arteriovenous access. Nephrol Dial Transplant 2005;20:1686–1692 16. Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Grohe C, Nickenig G, Woitas R, Skowasch D: Pulmonary hypertension in patients with chronic kidney disease on dialysis and with- out dialysis: results of the PEPPER-study. PLoS One 2012;7:e35310 17. Zlotnick DM, Axelrod DA, Chobanian MC, Friedman S, Brown J, Catherwood E, Costa SP: Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graftdys- function. Nephrol Dial Transplant 2010;25: 3090–3096. 18. Cirit M, Ozkahya M, Cinar CS, Ok E, Aydin S, Akcicek F, Dorhout Mees EJ: Disappearance of mitral and tricuspid regurgitation in haemodialysis patients after ultrafiltration. Nephrol Dial Transplant 1998;13:389–392. 19. Van Bortel LM, Struijker-Boudier HA, Safar ME: Pulse pressure, arterial stiffness, and drug treatment of hypertension. Hypertension 2001;38:914–921 20. Halpern SD, Taichman DB: Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009;136:37–43 21. S. Sanders, M.S. Frank, S.G. Rostand, et al., Metastatic calcification of the heart and lungs in end stage renal disease: detection and quantification by dual-energy digital 22. M. Akmal, R.R. Barndt, A.N. Ansari, et al., EXcess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy, Kidney Int. 47 (1995) 158–163. 23. O. Ifudu, Care of patients undergoing hemodialysis, N. Engl. J. Med. 339 (1998) 1054–1062. 24. T.M. Yu, Y.H. Chen, J.Y. Hsu, Systemic inflammation is associated with pulmonary hypertension in patients undergoing hemodialysis, Nephrol. Dial. Transplant. 24 (2009) 1946–1951. 25. M. Yigla, R. Banderski, Z. Azzam, et al., Development of pulmonary hypertension after arterio-venous access formation among end-stage renal disease patients, Ther.Adv. Respir. Dis. 2 (2008) 49–53. 26. Z. Abassi, F. Nakhoul, E. Khankin, et al., Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula:pathogensis and therapeutic prospective, Curr. Opin. Nephrol. Hypertens. 15 (2006) 353–360. 27. B.G. Jaar, J. Coresh, L.C. Platinga, et al., Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease, Ann. Intern. Med. 143 (2005) 174–183. 28. Swaminathan S, Shah SV: Novel inflamma- tory mechanisms of accelerated atherosclerosis in kidney disease. Kidney Int 2011;80:453– 463. 29. Dhaun N, Goddard J, Webb DJ: The endothelin system and its antagonism in chronic kid- ney disease. J Am Soc Nephrol 2006;17:943– 955 30. Nakhoul F, Yigla M, Gilman R, Reisner SA, Abassi Z: The pathogenesis of pulmonary hypertension in haemodialysis patients via arteriovenous access. Nephrol Dial Transplant 2005;20:1686–1692. 31. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010–2019. 32. Yigla M, Keidar Z, Safadi I, Tov N, Reisner SA, Nakhoul F: Pulmonary calcification in hemo- dialysis patients: correlation with pulmonary artery pressure values. Kidney Int 2004;66: 806–810. 33. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a nation- al study. Am J Kidney Dis 1998;31:607–617. 34. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouquer- ay B, Wheeler DC: Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011;26:1948–1955. 35. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S: Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011;58:374–382. 36. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD: Vita- min D therapy and cardiac structure and function in patients with chronic kidney dis- ease: the PRIMO randomized controlled trial. JAMA 2012;307:674–684. 37. EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482–2494. 38. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Lan- gleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW: A comparison of contini ous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296–301. 39. Channick RN, Simonneau G, Sitbon O, Rob- bins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hyper- tension: a randomised placebo-controlled study. Lancet 2001;358:1119–1123. 40. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148–2157.